Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00430144
Recruitment Status : Completed
First Posted : February 1, 2007
Last Update Posted : April 26, 2012
Information provided by (Responsible Party):
Sokbom Kang, National Cancer Center, Korea

Brief Summary:
-list item one, The purpose of this study is to evaluate the overall response rate of belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix

Condition or disease Intervention/treatment Phase
Cervical Cancer Drug: Belotecan(CKD-602) Phase 2

Detailed Description:
  • list item one, to evaluate toxicities of Belotecan
  • list item two, to evaluate duration of primary response for responding patients
  • list item three, to evaluate time to disease progression
  • list item four, to evaluate progression free survival and overall survival.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix
Study Start Date : January 2007
Actual Primary Completion Date : August 2009
Actual Study Completion Date : October 2010

Arm Intervention/treatment
Experimental: CKD-602 Drug: Belotecan(CKD-602)
Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Other Name: Camptobel

Primary Outcome Measures :
  1. overall response rate of belotecan (CKD-602) [ Time Frame: 1 week before the start of Cycle 4, 3 weeks later Cycle 6 or at discontinuation of study treatment, and then at least every 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed, patients with recurrent uterine cervical carcinoma who were unsuitable candidates for curative treatment with surgery and/or radiotherapy.
  • One of the following histologic types
  • Squamous cell carcinoma
  • Adenocarcinoma
  • Adenosquamous carcinoma
  • Clinically measurable disease
  • Performance status of 0, 1, 2 on the ECOG criteria

Exclusion Criteria:

  • Histology of neuroendocrine tumors
  • Patient previously treated with topoisomerase-I inhibitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00430144

Korea, Republic of
National cancer center
Seoul, Korea, Republic of
Sponsors and Collaborators
Sokbom Kang
Principal Investigator: Sokbom Kang National cancer cencer

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sokbom Kang, director, gynecologic oncology research branch, National Cancer Center, Korea Identifier: NCT00430144     History of Changes
Other Study ID Numbers: NCCCTS-06-214
First Posted: February 1, 2007    Key Record Dates
Last Update Posted: April 26, 2012
Last Verified: April 2012

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Phytogenic